IFNA1 and in situ carcinoma: SOCS 1-3 and CIS suppress the efficacy of IFN-α therapy by suppress IFN-α production (43, 44) and inhibiting JAK-STAT pathway to reduce the duration of antiviral genes expression (45, 46).